Rivoceranib

Scientific Overview: Oral selective VEGFR2 inhibitor; combined with camrelizumab — FDA approved HCC 2023. First China VEGFR2 TKI with FDA approval in combination

Mechanism of Action: VEGFR2-Selective TKI (oral)

Purity: ≥99%  |  Molecular Formula: C22H21N3O4S

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.